News Feature in 2021

The last three months saw financings focused on nucleic acid, cell therapy and genomic medicine focused technologies as Emma Dorey explains.

Drugs that target mast cells could provide novel options to treat disorders involving chronic allergic inflammation.

Funding for early-stage projects and global collaborations are aiming to breathe life into the fragile ecosystem for novel antibiotics.

In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.

We present a round up of selected biopharma, biotechnology and drug discovery stories published in September 2021 across the Springer Nature portfolio of journals.

We round up the key biopharma, biotechnology and drug discovery stories that were published in July and August 2021 across the Springer Nature portfolio of journals.

Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.

After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

COVID-19 has accelerated development and awareness of next-generation therapeutics, including mRNA vaccines, boosting the field’s dealmaking and investment activities.

July was awash with financings of potentially disruptive gene therapies.

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

Emma Dorey highlights five key deals, all from the US, in an otherwise quiet month.

This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

Emma Dorey explores the latest series B financing rounds from a range of several small biotech companies.

Dealmaking in the central nervous system disorder field has been dynamic in the past year despite COVID-19, and the market for therapies is set to expand in the next 5 years.

The COVID-19 pandemic has put new vaccine technologies into the spotlight and accelerated their development.

Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

Emma Dorey highlights key IPOs, gene therapy and oncology announcements in the second of her monthly round-ups.

Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.